Well-known somatic drivers of glioblastoma (GBM) heterogeneity, including PDGFRA, IDH1, EGFR, and NF1, have altered how we treat patients, diagnose disease, and design clinical trials (1, 2). This evidence concerns the gene NF1 and glioblastoma.